Kite grabs a stem cell bi­ol­o­gy ‘break­through’ in race for off-the-shelf T cell ther­a­pies

Look­ing for an edge in the race to de­vel­op block­buster off-the-shelf cell ther­a­pies to fight can­cer, Kite Ther­a­peu­tics has grabbed a li­cense for new T cell tech from UCLA that the biotech be­lieves can play a break­through role in the field of al­lo­gene­ic drugs.

Kite’s rep in R&D has been based on the first gen­er­a­tion of CAR-T drugs that ex­tracts cells from pa­tients and then cus­tomizes them with chimeric anti­gen re­cep­tors. Once in­fused back in­to pa­tients, they’re de­signed to track down and elim­i­nate can­cer cells. And Kite has one of the most ad­vanced pro­grams now in a piv­otal study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.